Ignite Creation Date:
2025-12-17 @ 2:44 PM
Ignite Modification Date:
2025-12-23 @ 10:23 PM
Study NCT ID:
NCT02061761
Status:
COMPLETED
Last Update Posted:
2023-03-24
First Post:
2014-02-12
Is Possible Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies
Sponsor:
Bristol-Myers Squibb
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2014-03-13
Start Date Type:
ACTUAL
Primary Completion Date:
2022-02-16
Primary Completion Date Type:
ACTUAL
Completion Date:
2022-02-16
Completion Date Type:
ACTUAL
First Submit Date:
2014-02-12
First Submit QC Date:
None
Study First Post Date:
2014-02-13
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2023-02-16
Results First Submit QC Date:
None
Results First Post Date:
2023-03-24
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-03-20
Last Update Post Date:
2023-03-24
Last Update Post Date Type:
ACTUAL